Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced it will present an update on its HIV fusion inhibitor program at the XVI International AIDS Conference in Toronto, Canada. A presentation describing the Company’s discovery of potent small molecule fusion inhibitors is scheduled for Thursday, August 17 from 12:30 to 2:00 p.m.
